Ixazomib is a pharmaceutical raw material used in the manufacturing of medications for multiple myeloma, a type of white blood cell cancer. It is administered orally and is combined with other drugs in therapeutic regimens.
Content scope: Information here supports chemical identification and industrial supply, research, and manufacturing contexts. It is not a therapeutic claim, medical advice, or drug-use instructions.
Sourcing or supplying this compound?
List your inventory or post a purchase request
CAS 1072833-77-2
Ixazomib citrate
pharmaceutical raw material
Methyl 1-(4-methoxyphenyl)-7-oxo-6-(4-(2-oxopiperidin-1-yl)phenyl)-4,5,6,7-tetrahydro-1H-pyrazolo[3,4-c]pyridine-3-carboxylate
pharmaceutical raw material
Ziconotide
pharmaceutical raw material
Omadacycline tosylate
pharmaceutical raw material
N-[2-(2-Oxo-2,3-dihydro-1H-indol-4-yl)ethyl]-N-propylpropan-1-amine N-oxide
pharmaceutical raw material
[(1R)-1-[[2-[(2,5-dichlorobenzoyl)amino]acetyl]amino]-3-methylbutyl]boronic acid
MXAYKZJJDUDWDS-LBPRGKRZSA-N
B([C@H](CC(C)C)NC(=O)CNC(=O)C1=C(C=CC(=C1)Cl)Cl)(O)O